N

Novavax
D

NVAX

8.47500
USD
0.43
(5.28%)
Market Closed
Volume
231,744
EPS
-3
Div Yield
-
P/E
-4
Market Cap
1,357,567,824
OverviewSignalsIdeasNews
Related Instruments
    A
    AEMD
    0.00400
    (1.04%)
    0.39000 USD
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    65.635 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    C
    CEMI
    0.02200
    (6.47%)
    0.35000 USD
    C
    CODX
    -0.04000
    (-3.64%)
    1.06000 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.14 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    V
    VXRT
    -0.05030
    (-7.97%)
    0.58050 USD
    More
News

Title: Novavax

Sector: Healthcare
Industry: Biotechnology
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.